TrialBritish journal of cancer2018

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.

Thomas Powles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.